Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.

Abstract

We evaluated the effect of troglitazone (given orally 400 mg/day) on glucose intolerance and on the plasma levels of tumour necrosis factor-alpha (TNF-alpha) in 12 obese patients with type 2 diabetes for 12 weeks. Troglitazone significantly decreased fasting plasma glucose, serum C-peptide, serum insulin and HbA1c levels. Plasma levels of TNF-alpha were significantly reduced by troglitazone administered for 8 and 12 weeks. Troglitazone administration significantly improved insulin resistance, but did not affect pancreatic beta-cell function as evaluated by the homeostasis model assessment (HOMA). In the present study, we reported for the first time that troglitazone administration significantly reduces plasma levels of TNF-alpha in obese patients with type 2 diabetes.

• Authors: A Katsuki, Y Sumida, K Murata, M Furuta, R Araki-Sasaki, K Tsuchihashi, Y Hori, Y Yano, E C Gabazza, Y Adachi
• Journal: Diabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 2 Issue 3 Pg. 189-91 (Jun 2000) ISSN: 1462-8902 [Print] England
• PMID: 11220554 (Publication Type: Journal Article)

Chemical References

• Blood Glucose
• C-Peptide
• Chromans
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Insulin
• Thiazoles
• Thiazolidinediones
• Tumor Necrosis Factor-alpha
• Troglitazone

Topics

• Blood Glucose (metabolism)
• C-Peptide (blood)
• Chromans (pharmacology, therapeutic use)
• Diabetes Mellitus (blood, drug therapy)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Glycated Hemoglobin (analysis)
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Insulin (blood)
• Insulin Resistance
• Obesity
• Thiazoles (pharmacology, therapeutic use)
• Thiazolidinediones
• Troglitazone
• Tumor Necrosis Factor-alpha (analysis, drug effects)